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Introduction
It has previously been shown that untreated children with 
attention deficit disorder with and without hyperactivity 
[AD(H)D] exhibit decreased 24-h heart rate variability 
[HRV] assessed via Holter ECGs (Buchhorn et al. 2012), 
albeit absence of altered HRV in short-term resting state 
recordings (Koenig et al. 2017). Autonomic imbalance, 
reflected by decreased HRV, is an important indicator of 
an enhanced cardiovascular morbidity and mortality risk 
in adults (Wulsin et al. 2015) as well as children and ado-
lescents (Farah et al. 2014; Vrijkotte et al. 2015). Ongoing 
debate in the AD(H)D literature predominantly focuses on 
the proarrhythmogenic side effects of psycho-stimulants 
(Triedman and Alexander 2010) and not on the well-known 
enhanced cardiovascular risk in patients with psychiatric 
disease (Neylon et al. 2013).
Nutritional intake of omega-3-fatty acids has a potential 
positive impact on cognition (Cooper et al. 2015) and emo-
tional dysregulation (Cooper et al. 2016; Messamore and 
McNamara 2016) associated with AD(H)D, although the 
existing evidence is mixed (Chang et al. 2017). The DOLAB 
study showed low blood long-chain omega-3 fatty acids in 
children with poor cognitive performance and behavior 
(Montgomery et al. 2013). Several prospective randomized 
controlled trials support the supplementation of omega-3-
fatty acids in children with AD(H)D to improve cognition 
(Gow et al. 2015; Widenhorn-Müller et al. 2014). Benefi-
cial effects on inattention in AD(H)D and healthy children 
(Bos et al. 2015) and other psychopathologies across the 
lifespan have also been reported (Sinn et al. 2010, 2012). 
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However, other studies showed that omega-3-fatty acid sup-
plementation effects cognition only in patients with reduced 
omega-3 levels (Hawkey and Nigg 2014). Further, omega-3 
fatty acids might improve cardiovascular function in chil-
dren with AD(H)D and thereby reduce the associated car-
diovascular risk, but more research is needed on this topic 
(Simopoulos 2008).
Previous research has shown that the supplementation 
of omega-3-fatty acid increases HRV (Carney et al. 2010; 
Christensen 2011; O’Keefe et al. 2006; Romieu et al. 2005). 
Here, drawing on routine clinical data from a pediatric car-
diology department, we aimed to illustrate potential effects 
of omega-3-fatty acid supplementation on 24-h HRV in 
children with AD(H)D, based on a case series. We assumed 
that children with AD(H)D would show increased 24-h 




A total of 18 cases, children and adolescents (age 
13.35  ±  2.8  years; size 156.8  ±  16.4  cm; weight 
50.2 ± 16.7 kg; BMI 20.0±4.1), who were referred to the 
outpatient clinic for pediatrics of the Caritas Hospital Bad 
Mergentheim between the years 2010–2016 were identified 
based on clinical files. Patients with a diagnosis of AD(H)
D, made by an external child psychiatrist according ICD-10 
diagnostic criteria, were referred to the pediatric cardiol-
ogy department for evaluation. All patients and their parents 
were informed about the multimodal therapy for AD(H)D 
(medications and behavioral therapy) and the possibility to 
supplement with omega-3-fatty acids. Of the cases included 
for analysis, some used omega-3 prior to stimulant treat-
ment (n = 4); some after termination of stimulant treatment 
because of the occurrence of side effects (n = 4); and the 
majority used omega-3 to reduce the cardiovascular risk dur-
ing stimulant treatment (n = 10). If the supplementation was 
not covered by health insurance, patients usually purchased 
different products based upon 1–2 g fish oil per day from 
discounters.
Hour ECG and analysis of heart rate variability
Two 24-h Holter ECGs were recorded. One before supple-
mentation with omega-3-fatty acids and a second one after 
143.7 days on average (range 42–490 days). Given the large 
variance in days between assessments due to the naturalistic 
design of the study, potential outcome effects were addressed 
in later analysis. A two-channel Holter monitor (Pathfinder, 
Spacelabs, Germany) was used for recording, while the chil-
dren followed their normal daily routines. All Holter record-
ings were reviewed by an experienced cardiologist and were 
edited to validate the system’s QRS labeling. Measures of 
HRV were calculated using inter-beat intervals between 
adjacent R-peaks. The Holter ECGs were analyzed as aver-
age values from the entire 24 h of analyzable data and addi-
tionally for circadian rhythm analysis as mean hourly values 
with regard to the time of day. Measurement and interpreta-
tion of HRV parameters in the current sample were standard-
ized according to the Task Force Guidelines (Task Force of 
the European Society of Cardiology and the North American 
Society of Pacing and Electrophysiology 1996). A minimum 
of 23 h of analyzable data and minimally 95% of analyzable 
RR intervals were required for the data to be included. The 
presentation focuses on three parameters,1 including heart 
rate (mean RR intervals) and one time-domain (the square 
root of the mean of the sum of squared differences between 
adjacent RR intervals (RMSSD)) and one frequency-domain 
(high-frequency HRV via fast Fourier transformation over 
the frequency of 0.15–0.4 Hz) measure of vagally mediated 
HRV.
Statistical analysis
To investigate changes in 24-h HRV recordings taken pre- 
and post-omega-3 supplementation, a threefold approach 
was chosen. First, the overall 24-h means of all indices were 
compared using paired t test for dependent samples. Second, 
mixed linear regression analyses were used to investigate 
main effects of supplementation (baseline versus omega-3) 
over repeated measures (main effect: hourly means) on all 
indices. To adjust for the time difference between repeated 
measures, we further tested such effect but found no sig-
nificant influence of the variance in days between assess-
ments. Third, we used a cosine function analysis approach 
(trigonometric linear regression) to model differences in 
circadian variation patterns and graphically display them. 
In a first step, three individual-level cosine function param-
eters were estimated for each individual 24-h time series 
to quantify the following circadian variation pattern (CVP) 
parameters: MESOR (the rhythm adjusted 24-h mean level), 
amplitude (the distance between MESOR and the highest 
maximum value of the cosine curve), and acrophase (the 
phase shift of amplitude from a given reference time point 
when the highest oscillation is reached). In a second step, 
these parameters were subjected to mixed linear regression 
1 The selection of parameters was limited during the review process. 
Upon request, the authors provide additional data on the standard 
deviation of RR intervals (SDNN), the percentage of pairs of adjacent 
RR intervals differing by more than 50  ms (pNN50), very low fre-
quency (VLF, < .04 Hz), and low frequency (LF, .04–.15 Hz) HRV.
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models to estimate the impact of omega-3 supplementation 
on MESOR, amplitude, and acrophase. Accordingly, time 
(baseline versus omega-3) differences were graphically illus-
trated using predicted values and the corresponding 95% CI 
of the standard errors of the prediction. All analyses were 
performed using Stata/SE (Version 14.1; StataCorp LP, Col-
lege Station, TX, US) with alpha set to .05. Graphs were 
prepared using GraphPad Prism (version 6.0, GraphPad 
Software Inc., USA).
Results
Descriptive statistics on 24-h as well as day- and night-
time means of the different indices by the time of measure-
ment are provided in Table 1. In mixed linear regression 
analysis on repeated measures of hourly means, omega-3 
supplementation had a significant main effect on mean RR 
(χ2(1) = 17.11, p < .001), RMSSD (χ2(1) = 7.23, p = .0072), 
and HF (χ2(1) = 9.29, p = .0023). The time of day had a sig-
nificant main effect on all dependent variables, including 
mean RR (χ2(17) = 818.21, p <.001), RMSSD (χ2(17) = 395.87, 
p <  .001), and HF (χ2(17) = 175.06, p <  .001). Analysis 
revealed significant interactions of omega-3 supplemen-
tation and the time of day on mean RR (χ2(17) = 118.39, 
p <  .001), RMSSD (χ2(17) = 651.34, p <  .001), and HF 
(χ2(17) = 55.08, p < .001). Findings are illustrated in Fig. 1. 
Changes in CPV from baseline to post-omega-3 supplemen-
tation are illustrated in Fig. 2. In mixed linear regression 
analysis on CVP parameters of HRV, omega-3 supplemen-
tation had a significant effect on the MESOR of mean RR 
(χ2(1) = 16.03, p < .001), RMSSD (χ2(1) = 6.92, p = .009), and 
HF (χ2(1) = 8.16, p = .004). Omega-3 supplementation had a 
significant effect on the amplitude of mean RR (χ2(1) = 4.92, 
p = .027) and RMSSD (χ2(1) = 4.62, p = .032), but not HF 
(χ2(1) = 1.65, p = .200). Omega-3 supplementation had no 
significant effect on any of the acrophase parameters.
Discussion
The present case series, drawing on routine clinical data, 
aimed to elucidate potential effects of omega-3 supple-
mentation on long-term recordings of HRV in children 
with AD(H)D. While the study has major methodological 
shortcoming, this case series indicates that omega-3 supple-
mentation in children with AD(H)D may reduce mean heart 
rate and increase its variability on a variety of time- and 
frequency-domain measures. Analysis or recordings col-
lected before and after omega-3 supplementation revealed 
changes in measures of the overall mean HRV and measure 
of amplitude in mean RR and RMSSD.
Table 1  Means of HRV indices at baseline and after omega-3 supplementation
Values are means and standard deviations in brackets for 24-h recordings; daytime recordings (6:00  am–6:00  pm) and nighttime recordings 
(6:00 pm–6:00 am); all observations n = 18; p values refer to paired t test (two-sided)
Mean RR mean RR interval, RMSSD square root of the mean of the sum of squares of differences between adjacent RR intervals, HF high-
frequency power (0.15–0.4 Hz)
24 h Day Night
Baseline Omega-3 p Baseline Omega-3 p Baseline Omega-3 p
Mean RR 667.24 (68.59) 726.82 (73.81) .001 589.39 (63.11) 639.88 (83.93) .003 744.12 (96.80) 811.79 (85.91) .006
RMSSD 34.488 (12.47) 45.06 (22.21) .017 25.47 (8.61) 34.04 (17.02) .017 43.40 (18.65) 55.74 (28.44) .021
HF 472.00 (264.65) 623.83 (341.70) .010 282.47 (163.91) 429.49 (257.40) .005 659.06 (399.10) 813.02 (468.75) .046
Fig. 1  Change in heart rate and heart rate variability based on hourly means from baseline to omega-3 supplementation; mean RR mean RR 
interval, RMSSD square root of the mean of the sum of squares of differences between adjacent RR intervals, HF high frequency (0.15–0.4 Hz)
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Reduced HRV is an important marker of enhanced car-
diovascular risk (Thayer et al. 2010). Only a few studies 
in children with AD(H)D to date have included cardio-
vascular endpoints. The majority of the existing studies 
addressed the association of cardiovascular adverse events 
and stimulant treatment (Dalsgaard et al. 2014). Stimulants 
have been reported to increase resting heart rate and ele-
vate systolic blood pressure compared to placebo in adults 
with AD(H)D (Mick et al. 2013).
However, the present case series has several limita-
tions that need to be addressed in future research. First, 
we studied a relatively small sample of children and ado-
lescents from a naturalistic clinical sample using routine 
data, referred to a pediatric cardiology department, who 
were not characterized in detail. In particular, a lack of 
standardized psychiatric assessment and information 
about child and adolescent psychiatric and psychothera-
peutic treatment limit the generalizability of the findings, 
as other treatments may underlie the increase in HRV. 
This includes a lack of standardized reporting of AD(H)D 
symptom severity before and after omega-3 supplementa-
tion. Further, the supplementation of omega-3 fatty acids 
was not standardized by any means (i.e., exact compound, 
dose, duration of supplementation).
We were not able to gain information on the EPA/DHA 
content and dose of the used brands of supplements and 
therefore are not able to determine whether appropriate 
doses of EPA/DHA have been taken and whether the ratio 
between EPA and DHA was appropriate. Further, we can-
not rule out potential effects of combined stimulant treat-
ment, as some patients used omega-3 prior to stimulant 
treatment, some after termination of stimulant treatment, 
and some during stimulant treatment. Future studies would 
do well to implement randomized, placebo-controlled 
designs and adhere to a strict protocol with respect to 
the measurement point of HRV, as we cannot rule out 
any other factors (i.e., changes in lifestyle habits such as 
physical activity) potentially influencing HRV. Further, 
we did not measure red blood cell PUFA levels, prohibit-
ing any conclusion with respect to the compliance with 
omega-3 supplementation, or a potential dose–response 
relation between omega-3 intake and changes in HR or 
HRV. Albeit these methodological limitations and short-
comings, the case series illustrates preliminary empirical 
data, illustrating that HRV may be an interesting biologi-
cal marker that may be used to assess effects of omega-3 
supplementation in ADHD. Longitudinal trials assessing 
the potential of omega-3-fatty acid supplementation to 
improve the risk of arrhythmias (London et al. 2007) and 
hypertension (Buchhorn and Christian 2014) in children 
with AD(H)D are warranted.
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Fig. 2  Change in heart rate and heart rate variability based on cir-
cadian variation pattern from baseline to omega-3 supplementation; 
mean RR mean RR interval, RMSSD square root of the mean of the 
sum of squares of differences between adjacent RR intervals, HF 
high-frequency power (0.15–0.4  Hz); dotted lines indicate the 95% 
confidence interval
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